Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Publication year range
2.
J Oncol ; 2019: 5879616, 2019.
Article in English | MEDLINE | ID: mdl-31827511

ABSTRACT

The recent introduction of the "precision medicine" concept in oncology pushed cancer research to focus on dynamic measurable biomarkers able to predict responses to novel anticancer therapies in order to improve clinical outcomes. Recently, the involvement of extracellular vesicles (EVs) in cancer pathophysiology has been described, and given their release from all cell types under specific stimuli, EVs have also been proposed as potential biomarkers in cancer. Among the techniques used to study EVs, flow cytometry has a high clinical potential. Here, we have applied a recently developed and simplified flow cytometry method for circulating EV enumeration, subtyping, and isolation from a large cohort of metastatic and locally advanced nonhaematological cancer patients (N = 106); samples from gender- and age-matched healthy volunteers were also analysed. A large spectrum of cancer-related markers was used to analyse differences in terms of peripheral blood circulating EV phenotypes between patients and healthy volunteers, as well as their correlation to clinical outcomes. Finally, EVs from patients and controls were isolated by fluorescence-activated cell sorting, and their protein cargoes were analysed by proteomics. Results demonstrated that EV counts were significantly higher in cancer patients than in healthy volunteers, as previously reported. More interestingly, results also demonstrated that cancer patients presented higher concentrations of circulating CD31+ endothelial-derived and tumour cancer stem cell-derived CD133 + CD326- EVs, when compared to healthy volunteers. Furthermore, higher levels of CD133 + CD326- EVs showed a significant correlation with a poor overall survival. Additionally, proteomics analysis of EV cargoes demonstrated disparities in terms of protein content and function between circulating EVs in cancer patients and healthy controls. Overall, our data strongly suggest that blood circulating cancer stem cell-derived EVs may have a role as a diagnostic and prognostic biomarker in cancer.

3.
G Chir ; 37(4): 167-170, 2016.
Article in English | MEDLINE | ID: mdl-27938534

ABSTRACT

Acute chylous peritonitis is defined as the onset of acute abdomen findings due to abrupt chylous fluid accumulation in the peritoneal space. A correct diagnosis of this condition is seldom made preoperatively. The optimal management of true chylous pancreatitis depends upon the underlying etiology. Thorough lavage of the abdomen and adequate drainage has proven to be an excellent treatment modality for acute chylous peritonitis, since resolution of chylous ascites usually occurs within the next few days. However, conservative treatment may be appropriate in selected cases. We present a case report and a brief review of the literature.


Subject(s)
Chylous Ascites/complications , Chylous Ascites/therapy , Drainage , Pancreatitis/complications , Pancreatitis/therapy , Therapeutic Irrigation , Abdominal Pain/etiology , Adult , Chylous Ascites/diagnosis , Drainage/methods , Female , Humans , Nausea/etiology , Pancreatitis/diagnosis , Therapeutic Irrigation/methods , Treatment Outcome , Vomiting/etiology
4.
Mol Biosyst ; 12(1): 219-32, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26588820

ABSTRACT

Classical Hodgkin lymphoma (cHL) is a malignancy with complex pathogenesis. The hallmark of the disease is the presence of large mononucleated Hodgkin and bi- or multinucleated Reed/Sternberg (H/RS) cells. The origin of HRS cells in cHL is controversial as these cells show the coexpression of markers of several lineages. Using a proteomic approach, we compared the protein expression profile of cHL models of T- and B-cell derivation to find proteins differentially expressed in these cell lines. A total of 67 proteins were found differentially expressed between the two cell lines including metabolic proteins and proteins involved in the regulation of the cytoskeleton and/or cell migration, which were further validated by western blotting. Additionally, the expression of selected B- and T-cell antigens was also assessed by flow cytometry to reveal significant differences in the expression of different surface markers. Bioinformatics analysis was then applied to our dataset to find enriched pathways and networks, and to identify possible key regulators. In the present study, a proteomic approach was used to compare the protein expression profiles of two cHL cell lines. The identified proteins and/or networks, many of which not previously related to cHL, may be important to better define the pathogenesis of the disease, to identify novel diagnostic markers, and to design new therapeutic strategies.


Subject(s)
Hodgkin Disease/metabolism , Proteome , Proteomics , Cell Line, Tumor , Flow Cytometry , Gene Expression Regulation, Neoplastic , Hodgkin Disease/genetics , Humans , Models, Biological , Protein Interaction Mapping , Protein Interaction Maps , Proteomics/methods
5.
J Comp Pathol ; 132(1): 96-100, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15629484

ABSTRACT

Ocular squamous cell carcinoma (OSCC) is a well-characterized tumour occurring spontaneously in cattle and other mammalian species but not previously reported in the goat. This report describes the histological features of well-differentiated OSCCs in twin goats. Biomolecular investigations led to the identification of Papillomavirus-related DNA sequences within the neoplastic ocular parenchyma of both animals, but immunohistochemical and ultrastructural studies failed to demonstrate viral particles. A putative role of Papillomavirus in the aetiology of OSCC is discussed, together with other possible causative factors.


Subject(s)
Carcinoma, Squamous Cell/veterinary , Eye Neoplasms/veterinary , Goat Diseases , Papillomavirus Infections/veterinary , Animals , Carcinoma, Squamous Cell/etiology , Carcinoma, Squamous Cell/pathology , DNA, Viral/analysis , Eye Neoplasms/etiology , Eye Neoplasms/pathology , Female , Goats , Immunoenzyme Techniques/veterinary , Male , Papillomaviridae/genetics , Papillomaviridae/isolation & purification , Papillomavirus Infections/complications , Papillomavirus Infections/pathology , Twins
7.
Int J Immunopathol Pharmacol ; 16(3): 269-76, 2003.
Article in English | MEDLINE | ID: mdl-14611731

ABSTRACT

The distribution of DNA of BK and JC human polyomaviruses (BKV and JCV) was investigated in samples from autopsies of different organs in 2 groups of patients: Human Immunodeficiency Virus -1 (HIV) positive and negative. Samples from various organs were analysed by a nested polymerase chain reaction (PCR) for the non-coding control and for the VP1 regions of both viruses. The results obtained showed that BKV DNA was present in both males and females with a higher prevalence in HIV-positive subject samples (spleen: 33%; kidney: 44%; brain: 22%, uterine cervix:100%; prostatic urethra: 50%). In prostatic urethra samples of HIV-positive subjects, the JCV DNA was revealed in a low percentage (33%), while it was not found at all in uterine cervix samples of both groups. The varying presence of BK and JC viral DNA in the different organs seems to reflect the different pathogenetic attitude of these viruses. JCV was mainly present in the brain (55%), confirming its typical neurotropism and its etiological role in neurological disorders found in immunodeficient patients. BKV, on the other hand, was mainly present in the kidney (44%) and in genital organs (uterine cervix: 100%; prostatic urethra: 50%) with the latter finding favouring the hypothesis of a possible sexual transmission of BKV. Furthermore, our results confirm the crucial role of the immune system in the persistence of human polyomaviruses in the host.


Subject(s)
BK Virus/genetics , HIV Seronegativity/genetics , HIV Seropositivity/genetics , HIV-1/genetics , JC Virus/genetics , Sequence Analysis, DNA , Adult , Aged , BK Virus/chemistry , BK Virus/isolation & purification , Brain Chemistry/genetics , Cervix Uteri/chemistry , Cervix Uteri/virology , Female , HIV Seropositivity/mortality , HIV Seropositivity/pathology , HIV Seropositivity/virology , HIV-1/chemistry , HIV-1/isolation & purification , Humans , JC Virus/chemistry , JC Virus/isolation & purification , Kidney/chemistry , Kidney/virology , Male , Middle Aged , Organ Specificity/genetics , Sequence Analysis, DNA/methods , Spleen/chemistry , Spleen/virology
8.
Presse Med ; 17(33): 1675-8, 1988 Oct 01.
Article in French | MEDLINE | ID: mdl-2973029

ABSTRACT

The toxic effects of 5-fluorouracil - an antimitotic drug widely used in the treatment of cancer - mainly affect the digestive tract and the blood. The 5 new cases presented here may be added to the 57 cases of cardiotoxicity reported in the literature. The clinical manifestations always consist of constrictive chest pain resembling angina pectoris and associated with disorders of repolarization on electrocardiographic tracing recorded during the painful episodes. The outcome is usually favourable after discontinuation of treatment, but it may also be fatal. Reintroduction of the drug in 28 patients resulted in myocardial necrosis in 4 cases and in death due to cardiogenic shock in 4 cases. The frequency of such side-effects does not seem to be influenced by age, sex, route of administration and previous pathology including cardiovascular diseases. They usually occur at the beginning of treatment irrespective of the dose administered. The mechanism through which 5-fluorouracil exerts its cardiotoxic effects is unknown, and 3 hypothesis have been put forward: an immunoallergic reaction after a sensitization period, a coronary spasm directly induced by the drug or due to the release of a vasopressive substance, or a direct toxic effect on the myocardium and pericardium.


Subject(s)
Fluorouracil/adverse effects , Heart Diseases/chemically induced , Arrhythmias, Cardiac/chemically induced , Female , Heart Diseases/etiology , Humans , Male , Middle Aged , Neoplasms/drug therapy , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...